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Neuregulin 1 (Nrg-1) isoforms have been shown to influence the
emergence and growth of oligodendrocytes, the CNS myelin-
forming cells. We have investigated how Nrg-1 signaling of
ErbB receptors specifically controls the early stages of oligo-
dendrocyte generation from multipotential neural precursors
(NPs). We show here that embryonic striatal NPs express mul-
tiple Nrg-1 transcripts and proteins as well as their specific
receptors, ErbB2 and ErbB4, but not ErbB3. The major isoform
synthesized by striatal NPs is a transmembrane type III isoform
called cysteine-rich domain Nrg-1. To examine the biological
effect of Nrg-1, we added soluble ErbB3 (sErbB3) to growing
neurospheres. This inhibitor of Nrg-1 bioactivity decreased mi-
tosis of NPs and increased their apoptosis, resulting in a sig-
nificant reduction in neurosphere size and number. When NPs
were induced to migrate and differentiate by adhesion of neu-
rospheres to the substratum, the level of type III isoforms
detected by RT-PCR and Western blot decreased in parallel
with a reduction in Nrg-1 fluorescence intensity in differentiating
astrocytes, neurons, and oligodendrocytes. Pretreatment of
growing neurospheres with sErbB3 induced a threefold in-
crease in the proportion of oligodendrocytes generated from
NPs migrating out of the neurosphere. This effect was not
observed with an unrelated soluble receptor. Addition of
sErbB3 during NP growth and differentiation enhanced oligo-
dendrocyte maturation as shown by expression of galactoce-
rebroside and myelin basic protein. We propose that both type
III Nrg-1 signaling and soluble ErbB receptors modulate oligo-
dendrocyte development from NPs.
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There is much interest in the molecular signals that regulate
development of multipotential neural precursors (NPs) and their
fate (Edlund and Jessell, 1999). Among candidate regulators are
neuregulin 1 (Nrg-1) growth factors and ErbB receptor tyrosine
kinases (Carraway and Burden, 1995; Burden and Yarden, 1997).
Neuregulins are encoded by a multigene family (NRG-1, -2, -3,
and -4), and all Nrg proteins contain an extracellular (EC) epi-
dermal growth factor (EGF)-like domain, which is essential for
bioactivity (Adlkofer and Lai, 2000). The NRG-1 gene regulates
early development of neurons and myelin-forming cells of the
peripheral nervous system and CNS as shown by studies in vitro
using recombinant Nrg-1 proteins and through analysis of NRG-1
mutants (Meyer and Birchmeier, 1995; Jessen and Mirsky, 1999;
Vartanian et al., 1999; Adlkofer and Lai, 2000). There are at least
15 soluble or transmembrane Nrg-1 proteins that on the basis of
different amino termini are grouped as type I [acetylcholine
receptor-inducing activity (ARIA) and neu differentiation factor
(NDF)], type II [glial growth factor 2 (GGF2)], and type III
isoforms [sensory-motor derived factor (SMDF) or cysteine-rich
domain (CRD-NRG)]. NRG-1 transcripts are found by in situ
hybridization in the germinal zone of embryonic day (E) 14 rat
and E18 mouse embryos, and the type III transcripts are the most
abundant (Corfas et al., 1995; Meyer et al., 1997). In addition,
various NRG-1 isoforms are synthesized in vitro by rat sensory
neurons, oligodendrocytes, and astrocytes (Raabe et al., 1997;
Vartanian et al., 1997; Francis et al., 1999).
How NRG-1 controls early stages of oligodendrocyte develop-
ment is not clear. Oligodendrocyte progenitors (OPs) are trig-
gered to divide by GGF2, and oligodendrocyte survival is en-
hanced by NDF and axon-derived Nrg-1 (Canoll et al., 1996;
Milner et al., 1997; Raabe et al., 1997; Shi et al., 1998; Fernandez
et al., 2000). An increase in oligodendrocyte differentiation was
observed in ARIA-treated cultures, whereas GGF2 and NDF
inhibited or even reversed their maturation (Vartanian et al.,
1994; Canoll et al., 1996, 1999). These contrasting results suggest
varying effects of Nrg-1 signaling on oligodendrocyte develop-
ment, which may depend on the degree of commitment of NPs to
the oligodendrocyte fate.
To investigate this question, the neurosphere system appears
particularly appropriate (Reynolds and Weiss, 1996; Gritti et al.,
1999) because it allows us to study which factors control NP
growth, the recruitment of differentiated cells from the NP pool
after neurosphere adhesion, and the commitment to oligodendro-
cyte differentiation. We show here that NPs of the E14 mouse
striatum germinative zone and striatal neurospheres mostly syn-
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thesize transmembrane type III Nrg-1 isoforms and that these
isoforms are downregulated during differentiation. ErbB2 and
ErbB4 are expressed during NP growth and differentiation. Using
soluble ErbB3 (sErbB3) receptor to inhibit Nrg-1 function, we
demonstrate that Nrg-1 controls the growth of NPs, increasing
their proliferation and survival. Moreover, soluble ErbB3 pre-
treatment of growing neurospheres specifically increased the
number of oligodendrocytes differentiating from NPs migrating
from the spheres. In contrast, addition of Nrg-1 appears to favor
a shift from oligodendrocyte to astrocyte generation. We propose
that NP growth is stimulated by endogenous type III Nrg-1 and
that this growth-promoting effect inhibits oligodendrocyte devel-
opment, which in turn can be triggered by a soluble ErbB
receptor.
MATERIALS AND METHODS
Preparation of neurosphere cultures. C57-Bl6 mice 14 d of age (IFFA-
CREDO) were killed in compliance with animal regulations of the
Pasteur Institute. The striata were removed from the embryos and
mechanically dissociated before cells were plated, as described previously
(Reynolds et al., 1992; Ben-Hur et al., 1998). Briefly, viable cells were
seeded at 1.2 3 10 5 cells/ml in uncoated T25 tissue culture flasks (Costar,
Cambridge, MA) or in 35 mm Petri dishes (Falcon, Plymouth, UK).
Culture medium consisted of DMEM/F-12 (1:1, v/v) supplemented with
B27 (both from Life Technology, Eragny, France) in the presence of 20
ng/ml of EGF (Sigma, St. Louis, MO). Media were supplemented with
20 ng/ml EGF every 2 d, and on every fourth day two-thirds of the media
was replaced with fresh media.
Adhesion of neurospheres. After 6 d in culture, three neurospheres of
the same size (80–100 mm in diameter) were plated onto 12 mm coated
coverslips (poly-D-lysine/fibronectin; 10 mg/ml each; Sigma) and 2 ml of
serum-free medium without EGF was then added to each well. After 2 d
of adhesion, the majority of cells had migrated out of the sphere.
Neurosphere treatment. Recombinant Human GGF2 (Cambridge Neu-
roScience Inc., Norwood, MA) was used at 2–200 ng/ml. For experi-
ments with soluble receptors (see description of production and purifi-
cation below), neurospheres were grown for 6 d as above in the presence
of different concentrations of sErbB3 (0.1–1 mg/ml) or soluble subunit b
of the glycine receptor (sGlyr; 0.5 or 1 mg/ml). Every 2 d, EGF, sErbB3,
and sGlyr were replenished. In some experiments, GGF2 (100 ng/ml),
sErbB3 (0.5 mg/ml or 6.6 mM), and sGlyr (0.5 mg/ml or 7.6 mM) were
added just after sphere adhesion for 2 d before immunocytochemical
staining.
RT-PCR analysis. Total RNA was purified with an RNAble kit (Euro-
bio, Les Ulis, France) from E14 striata, adult spinal cord, immortalized
Schwann cell cultures (MSC80; courtesy of A. Baron-Van Evercooren, la
Salpeˆtrie`re, Paris, France), or neurospheres cultured in suspension for
6 d or after 6 d of adhesion. Seven micrograms of total RNA were used
in RT reactions using Superscript II (Life technologies, Gaithersburg,
MD). One microliter of a 1:7 dilution of the cDNA synthesized from the
RT reaction was subjected to PCR in a 50 ml reaction with 0.2 mM dNTP,
1.5 mM MgCl2, 0.5 mM primers, and 1 ml (3.5 U) of Taq polymerase
(Expand High Fidelity PCR system, Roche, Meylan, France). Primers
used to analyze NRG-1 mRNAs encoding different isoforms are de-
scribed in Table 1 and localized in Figure 1. Reactions were run on a
Perkin-Elmer 2400 thermocycler (Roissy-Charles de Gaulle, France) (30
cycles; 94°C for 2 min, 94°C for 15 sec, 53°C for 30 sec, 68°C for 3 min,
and a final extension time at 72°C for 7 min).
Specific primers designed to amplify ErbB2, ErbB3, and ErbB4 are
listed in Table 1. cDNA synthesized by RT was diluted at 1:2 before PCR
amplification, then processed as described above with an annealing
temperature of 60°C. b-Actin was used as a control target sequence for all
amplifications.
Western blot. Proteins were extracted as described by Raabe et al.
(1996) from mouse E14 striata, floating or adhering spheres, and cultured
Schwann cells. Equivalent amounts of extracted proteins (15 mg) were
loaded on each lane of a 10% polyacrylamide gel (or 7.5% for the
anti-ErbB blots). After electrophoresis, proteins were transferred to a
polyvinylidene difluoride membrane (Roche). The membrane was incu-
bated with primary antibody overnight at 4°C and then with a secondary
antibody conjugated with peroxidase for 1 hr at room temperature. After
extensive washes, immunoreactive bands were visualized by enhanced
chemoluminescence (SuperSignal WestPico, Pierce, Brussels, Belgium or
ECL, Amersham Pharmacia, Buckinghamshire, UK). Primary antibodies
used were HRG-C19 goat polyclonal anti-Nrg-1 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA; 1:1000), goat IgG antibody against recombinant
human SMDF (R&D systems, Abingdon, UK; 1:500), and rabbit poly-
clonal antibodies against the cytoplasmic domain of ErbB receptors
(Santa Cruz Biotechnology), the precursor form of human ErbB2 (Neu,
C-18; 1:500), ErbB3 (C-17, 1:500), and ErbB4 (C-19; 1:500). Secondary
antibodies conjugated with peroxidase were RG-16 mouse monoclonal
anti-rabbit Ig (Sigma) used at 1:3000 and rabbit anti-goat IgG (Sigma)
used at 1:8000. Human recombinant SMDF (R&D) (10 ng per lane) was
used as control.
Immunocytochemistry of tissues and cells. The following antibodies
were used at the indicated dilution: goat polyclonal antibody to the C
terminus of the mature form of human Nrg-1 (HRG-C19; 1:200) and
rabbit polyclonal antibody to the C terminus of the precursor form of
human Nrg-1 (HRG-C20; 1:200) were obtained from Santa Cruz Bio-
technology. The rabbit polyclonal antibodies against the cytoplasmic
domain of the precursor form of human ErbB2 (Neu, C-18; 1:100) and
ErbB4 (C-19; 1:100) were also from Santa Cruz Biotechnology. Control
antibodies for Nrg-1 and ErbB staining were non-immune goat and rabbit
IgG used at the same final concentration (Jackson ImmunoResearch
Laboratories, West Grove, PA). TujI is a mouse IgG2a antibody against
neuron-specific class III b-tubulin (Babco, Richmond, CA; 1:500). The
rabbit polyclonal (1:200) and the mouse IgG1 (1:100) antibodies to glial
Table 1. Primer localization and sequences
Domains Sense Primer sequences
Ig-like domain of types I and II Nrg-1 Forward 59-TGCCTCCCAGATTGAAAGAAATG-39
GGF2 domain of type II Nrg-1 Forward 59-AACCTCAAGAAGGAGGTCAG-39
N-terminal domain of type III Nrg-1 Forward 59-TGAAGTGGGTATTTGTGGAC-39
EGF-like domain Reverse 59-CCATTCACACAGAAAGTTTT-39
Secreted form Reverse 59-GTTAATGTTCTCATGCGACAG-39
Transmembrane type (c) C-terminal form Reverse 59-CTCACTGAATGAGGTTCTCCTC-39
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fibrillary acidic protein (GFAP) were purchased from Dako (Glostrup,
Denmark) and Chemicon (Temecula, CA), respectively. Preoligodendro-
cytes were identified with mouse IgM antibodies O4 (a gift from S.
Barnett, Glasgow, Scotland; 1:20) and oligodendrocytes with O1 IgM
antibodies against galactocerebroside (a gift from R. Cohen, National
Institutes of Health; 1:5), and rabbit polyclonal antibody to myelin basic
protein (MBP; 1:50) was from Zymed laboratories (San Francisco, CA).
The nuclear marker DAPI (0.1 mg/ml final) was from Sigma (Paris,
France).
Cryosections (10 mm)on Superfrost Plus glass slides (Menzel-Glaser,
Braunschweig, Germany) were prepared from striata of E14 mice or from
floating neurospheres that had been fixed in 4% paraformaldehyde in
PBS overnight at 4°C. Adherent neurospheres were fixed the same way
for 30 min at room temperature before staining. Primary antibodies were
applied overnight at 4°C or 30 min at room temperature (O4 staining) in
a humidified chamber. Slides were then incubated in appropriate second-
ary antibodies and with DAPI for 30 min at room temperature. For
intracellular labeling with HRG-C19, HRG-C20, ErbB2, and ErbB4
antibodies, a permeabilization with PBS 0.1% Triton X-100 was per-
formed for 20 min at room temperature before blocking with normal goat
serum. Double and triple immunolabeling were performed as described
previously (McKinnon et al., 1990; Ben-Hur et al., 1998).
Preparations were photographed with a Leica microscope (DMRB
model) equipped with a Coolsnap camera system (Princeton Instru-
ments, Evry, France). For the confocal analysis, a Leica Optovar inverted
microscope equipped with a Leica model TCSAD Confocal Instrument
was used (courtesy of E. Perret, Department of Retrovirology, Pasteur
Institute, Paris).
Purification of soluble receptors. The soluble form of ErbB3 receptor
was constructed using the ectodomain of ErbB3 cloned in frame to an Fc
portion (hinge, CH2, and CH3 domains) of human immunoglobulin G,
called CDM7-IgB-3, courtesy of Y. Yarden (Chen et al., 1996). The
sequence coding for the ectodomain was released by a BamHI and
EcoRV digestion and purified on an agarose gel. The purified DNA
fragment was then ligated in frame in a BamHI–EcoRV-digested
pCDNA3-Myc-His vector (Invitrogen, Groningen, The Netherlands).
The rat glycine receptor b subunit (sGlyr) was cloned by RT-PCR from
adult rat spinal cord RNA using primer with an ApaI site underlined
(forward: AACGGGCCCGTTTTCAAGATGAAGTTTTCGTTG; re-
verse: TTCGGGCCCTAAATATATAGACC). The resulting PCR prod-
uct was purified on an agarose gel and cloned in a pCR-TOPO vector
(Invitrogen). The sGlyr was then subcloned in pCDNA3-Myc-His vector
in ApaI sites. The various constructs and their orientation were verified
by sequencing. The constructs were transfected into Chinese hamster
ovary (CHO) cells using the DAC30 lipofection reagent (Eurogentec,
Lie`ge, Belgium) selected with G418 at 500 mg/ml 48 hr later (Life
Technologies, Gent, Belgium). Selected recombinant CHO cells were
then cloned by dilution, and several clones were tested and selected for
the expression of the ectodomain of ErbB3 in the cytoplasm.
We extracted 40 3 10 6 cells in 40 ml of an ice-cold buffer containing 8 M
urea, 0.1 M NaH2PO4, and 0.01 M Tris, pH 8.0. Cells were homogenized in
a Potter tissue homogenizer and then centrifuged for 15 min at 15,000 3 g
at 4°C. The supernatant was loaded on an Ni-NTA column (Qiagen,
Westburg, Leusden, The Netherlands) equilibrated with extraction buffer.
The use of urea as a denaturing agent resulted in enhanced attachment of
recombinant sErbB3 to Ni-NTA and therefore increased the yield of
purification. After loading, the column was washed with a 0–100% gradient
of refolding solution (0.02 M Tris, pH 7.4, 500 mM NaCl, and 20% glycerol)
at 0.5 ml/min for 90 min. Two steps of elution were performed in refolding
solution containing successively 10 and 250 mM imidazole. sErbB3 was
present in the last elution step as demonstrated by Western blotting using
anti-myc antibodies (see Fig. 4A). sGlyr was purified as described for
sErbB3 on Ni-NTA gel except that the extraction buffer also contained
0.25% sodium deoxycholate. The refolding step was replaced by a wash in
extraction buffer adjusted to pH 6.3, and the elution was performed with
extraction buffer adjusted to pH 4.5 and containing 2% 3-[(3-chola-
midopropyl)dimethylammonio]-1-propanesulfonic acid. sGlyr was selec-
tively eluted as demonstrated in Figure 4A and appeared as a 75 kDa
species. The higher than predicted molecular weight (MW) is probably
attributable to the MW of the Tag (6.7 kDa) and glycosylation. Silver gel
performed at the end of each soluble receptor purification did not reveal
any contaminant. To test the biological activity of sErbB3, a tritiated
thymidine assay was run on rat Schwann cells (Mahanthappa et al., 1996;
Keirstead et al., 1999) cultured in the presence of increasing doses of
sErbB3 alone or with 20 ng/ml of GGF2.
Cell proliferation assay. Two different assays were used. First, the
neurospheres were grown in suspension for different times and in the
presence of 10 mM bromodeoxyuridine (BrdU; Sigma) for the last 24 hr.
These spheres were plated on poly-D-lysine/fibronectin-coated coverslips
for 30 min at 37°C to allow neurosphere adhesion but not differentiation.
Neurospheres were then fixed for 30 min at room temperature. The
spheres were then processed for BrdU staining (Ben-Hur et al., 1998)
with a mouse IgG1 against BrdU from Becton Dickinson (San Jose, CA;
1:50) and colabeled with DAPI.
Second, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT; Sigma) reduction assay (Mosmann, 1983) was used to test
the effect of exogenous Nrg-1 on NP growth. We cultured 1000 viable
cells/ml in 96-well plates in the presence of 2, 20, or 200 ng/ml of GGF2
for 2 d before addition of MTT at 1 mg/ml. After 4 hr at 37°C, 100 ml of
dissolving solution (20% SDS, 1:2 dimethyl formamide, 2% acetic acid,
0.06% HCl 1N) was added to the wells. The plates were incubated for 20
min at room temperature for color development and then assayed by
measuring the optical density (O.D.) at 570 nm 2 O.D. at 630 nm.
Background absorbance of medium in the absence of cells was
subtracted.
TUNEL analysis. TUNEL method was used to label apoptotic nuclei
in floating neurospheres as described previously (Gavrieli et al., 1992).
Briefly, after 2 or 6 d in culture, floating neurospheres were adhered 30
min as above, then fixed and permeabilized for 40 min with 0.5% Triton
X-100 in PBS. Cells were then incubated for 10 min in terminal-
deoxynucleotidyl-transferase (TdT) buffer (Roche) before incubation
with TdT and biotin-labeled dUTP (Roche) for 30 min at 37°C. Finally,
biotin was revealed by streptavidin–Cy3 and colabeled with DAPI.
Statistics. For each experimental condition, cell counting was per-
formed blind in three independent experiments. The total number of
spheres and the size of 50 floating neurospheres in triplicate Petri dishes
were analyzed with a Leica microscope (DMIL) equipped with a grad-
uated eye-piece. To determine the percentages of BrdU- and TUNEL-
positive cells in each experiment, all cells in 30 spheres per slide were
counted with a Leica microscope (DMRB model). In experiments with
adherent neurospheres, we counted the number of each type of differ-
entiated cells and the total number of cells per sphere. In the latter case,
we scanned the DAPI staining of the entire sphere outgrowth with the
Coolsnap camera and counted the nuclei with NIH Image software
(Version 1.62).
The mean fluorescence per cell of Nrg-1 expression was measured for
NPs and differentiated cells with NIH image software on confocal
images of neurospheres stained with either HRG-C20 or HRG-C19
antibodies. Data points from the MTT assay were averages from five
independent experiments. All values are shown as mean 6 SEM. The
statistical significance of differences between control and experimental
conditions was analyzed using the one-tailed Student’s t test (Excel 98).
A value of p , 0.05 is considered statistically significant (*p , 0.05; **p ,
0.02; ***p , 0.01).
RESULTS
To study Nrg-1 signaling in multipotential NPs, we isolated the
striatal periventricular zone of E14 mouse embryos and cultured
the dissociated cells as neurospheres (Svendsen and Rosser, 1995;
Reynolds and Weiss, 1996). These striatal NPs express nestin and
form spheres after growth in EGF for 6 d. When neurospheres
are plated onto polylysine/fibronectin-coated coverslips without
EGF, NPs migrate out of the spheres and differentiate into cells
of the astrocytic, neuronal, and oligodendrocytic lineages. We
will first describe which Nrg-1 isoforms and receptors are ex-
pressed and then the biological effects of Nrg-1 endogenous
signaling in this system.
Neuregulin 1, ErbB2, and ErbB4 are expressed in E14
striatum and neurospheres
We first characterized by RT-PCR and Western blot which Nrg-1
isoforms were expressed in striatum and in neurospheres. We
designed sets of primers that distinguish between the different
amino termini of type I and/or II as well as type III isoforms by
positioning the forward primer in regions specific for each amino
terminus and positioning the reverse primer in the EGF-like
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domain present in all NRG-1 isoforms (see Materials and Meth-
ods) (Fig. 1A). The adult spinal cord was used as positive control
because the three types of NRG-1 isoforms are expressed in this
region (Shinoda et al., 1997).
In adult spinal cord and E14 striatum, Ig–EGF primers de-
tected three bands from 480 to 370 bp that correspond to both
type I and II isoforms either with or without a glycosylation
domain (Fig. 1B). A weak signal was detected only at 480 bp in
neurospheres (Fig. 1B). GGF2–EGF primers also detected three
bands of type II isoforms (from 570 to 460 bp) in spinal cord and
E14 striata, but there was no signal in neurospheres (Fig. 1B). In
contrast, the type III isoform (CRD–EGF primers) gave an
intense 500 bp band and a weaker band at 440 bp in spinal cord,
striatum, and growing neurospheres with a decrease in intensity
in differentiated spheres (Fig. 1B). Because the type III NRG-1
transcripts appear the most abundant, we designed other sets of
primers that parse type III transcripts into secreted (Fig. 1A, s)
and transmembrane isoforms with a long and short cytoplasmic
tail (Fig. 1, A, C, a and c, respectively). Although the spinal cord
and E14 striatum expressed these three type III isoforms, only the
secreted form (s, 732 bp band) and the transmembrane form with
the long C-terminal domain (a, 1852 bp band) were weakly
detected in floating neurospheres (Fig. 1C). The 1852 bp product
was cloned into a pCRII vector, and sequencing of seven clones
revealed coding regions for type III transmembrane type (a)
isoforms, corresponding to a, b1, and b2 Nrg-1 variants. These
variants are generated by alternative splicing in the region coding
for the EGF–juxtamembrane portion (Fig. 1A). In our experi-
ments, the EC domain of the b-2a type III variant that we cloned
showed 91.5% identity with the EC domain of rat RASC9 se-
quence (Bermingham-McDonogh et al., 1997), 65.3% identity
with the chick b-2a NRG–CRD domain (Yang et al., 1998), and
81.3% identity with human soluble SMDF (Ho et al., 1995).
Western blot analysis using antibodies directed against recombi-
nant human SMDF (Fig. 1D, 45 kDa band) revealed an 80 kDa
doublet corresponding to the MW of the transmembrane SMDF
form in E14 striata, in Schwann cells (Rosenbaum et al., 1997),
and in growing neurospheres (Fig. 1D). The soluble SMDF
protein (33–45 kDa) was not detected (Fig. 1D) but may have
been lost during tissue extraction. The 80 kDa product was also
detected by polyclonal anti-Nrg-1 antibodies (HRG-C19) recog-
nizing all Nrg-1 isoforms (data not shown). The intensity of bands
detected by the anti-SMDF and anti-Nrg-1 antibodies was de-
creased in differentiated neurospheres, an observation that cor-
relates with the RT-PCR data (Fig. 1B,C).
We then analyzed ErbB2, -3, and -4 expression in E14 striata
and growing and adherent neurospheres. Although we consis-
tently detected both ErbB2 and ErbB4 by RT-PCR and Western
analysis, an ErbB3 signal was not detected in these samples (Fig.
2A,B). Positive controls include Schwann cells, which showed a
Figure 1. RT-PCR and Western blot analysis of NRG-1 isoforms in E14
striatum and neurospheres. A, Schematic representation of the different
splice variants of the NRG-1 gene modified from Adlkofer and Lai
(2000). The domains where the forward and reverse primers were placed
are shown by arrows. For type I, the forward primer was placed in the
Ig-like domain (Ig), for type II in the amino terminus GGF2 domain
(GGF2) (signal peptide, SP), and for type III in the CRD region (CRD).
Each primer was used in combination with a reverse primer specific for
the EGF-like domain (EGF ) common to all NRG-1 isoforms (B). To
identify the different type III forms, the CRD primer was combined with
one located in the short extracellular C-terminus domain of soluble
isoforms ( s) or with primers able to identify the long and short trans-
membrane domains because of their location in the C-terminus tail (a or
c) (C). B, Total RNA of neurospheres grown for 6 d (Undiff.) or after an
additional 6 d of adhesion (Diff.) was subjected to RT-PCR and compared
with E14 mouse striata (St. E14 ). Adult spinal cord (Spi. A) was used as
control. The Ig-EGF primers gave a very weak band of 480 bp for type I
and II isoforms in neurospheres, whereas the signal was somewhat stron-
ger in striata and spinal cord and made of three different bands. Type II
NRG-1 products were present in striata and spinal cord but not in
neurospheres. Type III forms gave a strong signal (500 bp) and a weak
band at 440 bp in neurospheres that decreased after adhesion. The most
intense signal was seen in E14 striata and adult spinal cord. C, By
RT-PCR, the RNAs encoding type III isoforms and made by undifferen-
4
tiated neurospheres were the soluble ( s) and the longest type (a) trans-
membrane isoform. There was no signal for the isoform with the shortest
cytoplasmic domain (c). E14 striata and adult spinal cord expressed all
three C-terminal isoforms. An additional band of an unidentified nature
is present in adult spinal cord. D, Western blots of lysates of the E14
striata and neurospheres were compared with those of cultured neonatal
mouse Schwann cells (Schwann). Antibodies directed against recombi-
nant human SMDF identify in E14 striata, growing neurospheres, and
Schwann cells a broad doublet of ;80 kDa that is undetectable in
differentiated neurospheres. These antibodies recognized a preparation of
purified soluble SMDF (rSMDF ) at 45 kDa.
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strong ErbB3 signal using both techniques but no ErbB4 (Fig.
2A,B) (Grinspan et al., 1996; Vartanian et al., 1997).
Together, these results indicate that in E14 striatum and NPs
derived from this region, the predominant Nrg-1 products consist
of type III 80 kDa transmembrane isoforms, which are downregu-
lated in differentiating neurospheres. These Nrg-1 isoforms most
likely signal through ErbB2–ErbB4 heterodimers or ErbB4
dimers expressed by NPs.
Nrg-1 and ErbB receptors are coexpressed in neural
precursors but levels of expression vary
during differentiation
To determine whether Nrg-1 isoforms and their receptors were
expressed in the same or different NPs in vivo and in vitro, we used
confocal fluorescence microscopy to examine cryosections of E14
striata and floating neurospheres double labeled with polyclonal
antibodies to the mature form of Nrg-1 (HRG-C19 antibody) and
to the ErbB2 or ErbB4 receptor. Merging of the two images taken
in the fluorescein (ErbB receptor) and rhodamine (Nrg-1) mode
showed that the majority of striatal cells (Fig. 3A,B) and NPs
(Fig. 3C,D) coexpressed at least one of these two ErbB receptors
and Nrg-1. ErbB2 and ErbB4 staining was detected both in the
cell cytoplasm and at the membrane whereas Nrg-1 staining was
mostly associated with the membrane (Fig. 3A’–D’). The orange
color resulting from colocalization of Nrg-1 with ErbB2 or ErbB4
was mostly associated with the plasma membrane and appears
more frequent in cells at the periphery of the neurosphere. These
observations correlate well with the synthesis of a transmembrane
Nrg-1 isoform by NPs and suggest that signaling through the
ErbB2 and ErbB4 receptors occurs mostly in an autocrine or
paracrine way, or both.
We then examined whether expression of the Nrg-1 and ErbB
receptors changes during differentiation of NPs into different
CNS cell types after adhesion of neurospheres. Scattered, punc-
tuate staining of Nrg-1, ErbB2, and ErbB4 was detected in both
undifferentiated and differentiated cells of the sphere outgrowth
(Figs. 3, 4). Quantitative analysis by confocal microscopy showed
an important decrease of intensity of Nrg-1 expression when
compared with NPs in neurospheres (Fig. 3K). The comparison
between single labeling for Nrg-1 and double labeling with cell-
specific markers showed that Nrg-1 was mostly expressed by
O4-positive preoligodendrocytes (Fig. 3E,F, white arrowheads) as
well as by multiprocessed neuronal cells stained for the isoform
III of tubulin in their cell bodies and processes (Fig. 3G,H, white
arrowheads). In contrast, some mature astrocytes were negative
for Nrg-1 (Fig. 3 I,J, black arrowheads), whereas immature astro-
cytes showed more Nrg-1 staining (Fig. 3 I,J, white arrowheads).
Double labeling illustrated in Figure 4 showed that ErbB2 was
expressed by the majority of differentiated cells (Fig. 4A,C,E,
white arrowheads), although some oligodendrocytes, neurons, and
astrocytes were negative for ErbB4 (Fig. 4B,D,F, black arrow-
heads). Thus the majority of differentiated cells still express Nrg-1
and its two receptors.
Nrg-1 controls the growth and survival
of neurospheres
To investigate the effects of Nrg-1 on NPs, we first tested whether
addition of GGF2 (at 50 or 200 ng/ml) to the medium of growing
neurospheres would increase their rate of formation or their size,
but we observed no significant effect compared with untreated
spheres after 6 d of growth (data not shown). We also investi-
gated whether ErbB2 and ErbB4 receptors were phosphorylated
after addition of GGF2, using immunoprecipitation followed by
phosphotyrosine antibody labeling (Vartanian et al., 1997). A
weak signal for phosphorylated ErbB4 was found in two experi-
ments on neurospheres, but no definite phosphorylated ErbB2
band was detected (data not shown).
Given the expression of Nrg-1 isoforms and ErbB receptors in
neurospheres (Figs. 1–4), we reasoned that endogenous Nrg-1
had probably saturated the receptors at 6 d. We therefore used a
different assay to test GGF2 effects in conditions of minimal
endogenous Nrg-1. Freshly dissociated striatal NPs were seeded
with different concentrations of GGF2, and their growth was
measured after only 2 d by MTT assay. In this condition, GGF2
addition produced a small but significant increase in cell growth
(1.5-fold with 2 ng/ml of GGF2, twofold with 20 ng/ml of GGF2,
and 1.8-fold with 200 ng/ml of GGF2 in comparison with control
condition). These results suggest a role of Nrg-1 in the early
growth of NPs. Therefore, we engineered a cDNA encoding
sErbB3, the amino-terminal domain of which specifically binds to
Nrg-1 ligands, which we purified from transfected CHO cells.
Although soluble ErbB4 has been used before as an Nrg-1 inhib-
itor (Pinkas-Kramarski et al., 1997; Vartanian et al., 1999), more
recent studies have revealed that at least seven ligands bind to
ErbB4 (Nrg-1, -2, -3, and -4, betacellulin, epiregulin, and heparin-
binding EGF) (Olayioye et al., 2000). Thus we chose sErbB3 as a
specific inhibitor of Nrg-1 isoforms assuming that it would bind to
the type III isoforms made by neurospheres. As a control for this
inhibitor, we prepared a soluble form of the b subunit of the
glycine receptor (sGlyr), which does not bind glycine (Betz et al.,
Figure 2. Expression of ErbB receptors in neurospheres before and after
adhesion. A, RT-PCR analysis: RNA was extracted from four samples
(denominated as in Fig. 1D) and from Schwann cells used as positive
control. ErbB2 gave a signal in all samples. ErbB3 is absent in E14 striata
and neurospheres but present in Schwann cells and adult spinal cord.
ErbB4 is stronger than ErbB2 in all CNS samples and absent in Schwann
cells. B, Western blot analysis was performed on extracts denominated as
in Figure 1. Anti-ErbB2 antibodies detect a signal ;180 kDa in all
samples. Anti-ErbB3 antibodies detect a band (160 kDa) only in cultured
Schwann cell extracts but not in E14 striata or growing or adhering
neurospheres. Anti-ErbB4 antibodies detect a 185 kDa signal in all
samples except Schwann cells.
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1999) and therefore could not interfere with a putative glycine
signaling in neurospheres. The purified sErbB3 and sGlyr had a
MW of 80 and 75 kDa, respectively, as shown by Western blot
analysis (Fig. 5A). The biological activity of sErbB3 was analyzed
using a tritiated thymidine incorporation assay on rat Schwann
cells. We first tested whether sErbB3 had an effect on cell prolif-
eration of rat Schwann cells grown without GGF2 in the presence
of increasing doses of sErbB3 and found no significant changes
compared with untreated cultures even at the highest dose (Table
2). We then assayed whether rat Schwann cell mitosis induced by
Figure 3. Nrg-1, ErbB2, and ErbB4 expression in E14 striatum and neurospheres. A–D, Confocal imaging was done after double immunolabeling with
goat antibody to human Nrg-1 (HRG-C19, rhodamine in A–D) and a rabbit antibody against human ErbB2 (fluorescein; A, C) or ErbB4 receptor
(fluorescein; B, D). The merged images show the coexpression of each ErbB receptor with Nrg-1 in orange in striatum (A, B) and neurospheres (C, D).
A’–D’, The strong membrane signal of individual cells (arrows) is shown in the close-up corresponding to the frames indicated in A–D. V, Ventricule.
E–J, Expression of Nrg-1 in differentiated cells in the outgrowth from neurospheres. Note that Nrg-1 is in red in E and F and in green in G–J and that
nuclei are stained blue by DAPI. E, F, Six days after sphere adhesion, many cells in the outgrowth are preoligodendrocytes labeled with O4 antibody
( green). Single (E) and double (F) label show scattered dots of Nrg-1 (red, HRG-C20 antibody) colocalized with O4 staining. White arrows in F indicate
three double-labeled cells: one is strongly O4 positive (lef t arrow), whereas the two cells at right arrows are weakly stained with O4 antibodies. Nrg-1 is
also detected in a double-labeled spindle-shaped OP in the left corner of F. G, H, Neuronal cells stained with TujI antibody (red) express Nrg-1 ( green,
HRG-C20 antibody) as indicated by the orange label in three cells indicated by white arrows in H. I, J, A cell with a weak GFAP staining (red) shows a
strong signal for Nrg-1 ( green, HRG-C20 antibody) resulting in orange labeling of this immature astrocyte (J, white arrow). In contrast, strongly
GFAP-positive astrocytes (in red) are not stained by Nrg-1 antibody (compare I and J at the two black arrows). Scale bars, 10 mm. K, Quantitative analysis
of confocal images of cells stained with two different antibodies to Nrg-1 proteins (HRG-C19 and HRG-C20). Fluorescence intensity of Nrg-1 labeling
decreased in differentiated cells of adherent neurospheres after 6 d when compared with undifferentiated NPs within neurospheres.
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20 ng/ml of GGF2 was inhibited by increasing concentrations of
sErbB3. The soluble receptor used at 250 ng/ml inhibited 50% of
the 15-fold increase in proliferation induced by GGF2 (Table 2).
Finally, Schwann cell survival was measured in the presence of
increasing doses of sErbB3 (up to 1000 ng/ml) by a calcein-AM
fluorescent assay (Gatti et al., 1998), which did not reveal any
significant cell death compared with untreated Schwann cells
(data not shown).
To evaluate the effects of this Nrg-1 inhibitor on neurosphere
growth, we added 0.1 mg/ml to 1 mg/ml of sErbB3 or 1 mg/ml of
sGlyr at the time of seeding of the NPs. sErbB3 decreased the
neurosphere size but did not inhibit neurosphere formation (Fig.
5B). After 6 d of growth in suspension, there was a significant and
dose-dependent reduction in both the size and number of neuro-
spheres growing in the presence of sErbB3, whereas addition of
sGlyr had no effect compared with neurospheres grown in control
medium (Fig. 5C,D). To determine whether sErbB3 inhibited cell
proliferation or survival, or both, we first evaluated DNA synthe-
sis by adding BrdU during the last 24 hr to neurospheres cultured
for 2 or 6 d in the presence or absence of sErbB3 (0.5 mg/ml) and
sGlyr (0.5 mg/ml) (Fig. 5E). The same experimental design and
time points were used to assay apoptosis by the TUNEL method
(Fig. 5F). sErbB3 significantly decreased cell proliferation and
increased the percentage of apoptotic cells after 2 or 6 d in
culture (Fig. 5E,F). However, these effects varied with time. At
2 d, sErbB3 decreased the proliferative index 4.5-fold (from 27 6
1% in control condition to 6 6 3%), whereas at 6 d the decrease
was merely 13% (from 81 6 2% to 68 6 2%) (Fig. 5E), suggesting
either a low efficiency of sErbB3 blocking after 6 d or that other
mitogens were stimulating proliferation at this stage. In contrast,
sErbB3 treatment increased NP apoptosis two to three times at
both time points, whereas there was no significant change in the
apoptosis index between 2 and 6 d in control and sGlyr-treated
cultures (Fig. 5F). These experiments demonstrate that endoge-
nous Nrg-1 enhances the growth and survival of NPs in
neurospheres.
sErbB3 treatment of neurospheres enhances
oligodendrocyte generation after adhesion
To investigate whether sErbB3 influences cell differentiation after
adhesion of neurospheres, we analyzed by immunocytochemistry
the different CNS cell types in the outgrowth of control or
sErbB3-treated neurospheres (as described above). In one group,
the inhibitor was washed out before neurosphere adhesion,
whereas it was added for 2 d in the other group (Fig. 6). The total
number of cells that had migrated out of each neurosphere was
determined for each condition (Fig. 6A), and the respective ratios
of oligodendrocytes, neurons, and astrocytes to this total cell
number were determined (Fig. 6B). As predicted from the results
of the experiments on neurospheres (Fig. 5), neurosphere treat-
ment with sErbB3 before adhesion significantly decreased the
total number of cells migrating out of neurospheres, whereas
sErbB3 added after adhesion had no such effect (Fig. 6A). Most
of the outgrowth cells were still undifferentiated NPs at 2 d.
Figure 4. ErbB expression in differentiated cells. Double
labeling with nuclei stained blue by DAPI. Note that ErbB
receptors are in red in A and B and in green in C–F. A, B,
ErbB2 ( A) and ErbB4 ( B) (red) are detected in both the
cell body and processes of preoligodendrocytes producing
an orange staining of the cytoplasm around the blue nucleus
(white arrowheads). In B, note one oligodendrocyte
strongly stained by O4 ( green), which is ErbB4 negative
(black arrowhead). C, D, Neurons labeled with TujI (red)
and ErbB2 ( green) show orange label in their cell bodies
and processes (C, white arrowheads). In contrast, only a few
TujI-positive cells express ErbB4 (orange cells in D at white
arrowheads). Other bipolar neuronal cells are mostly red,
showing weak or no labeling for ErbB4 (D, black arrow-
heads). E, F, All astrocytes coexpress GFAP (red) and
ErbB2 ( green), resulting in orange staining (white arrow-
heads), but some do not express ErbB4 (red-labeled astro-
cytes at black arrowheads in F ). Scale bar, 10 mm.
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Among the differentiated cells, surprisingly, the ratio of O4-
positive preoligodendrocytes to total cells was three times greater
after adhesion of sErbB3-treated neurospheres (15 6 3%) than of
control (5 6 1%) or sGlyr-treated neurospheres (6 6 2%). This
effect was specific for preoligodendrocytes because the ratio of
GFAP-positive astrocytes or TujI-positive neuronal cells was not
increased. Addition of sErbB3 after adhesion did not increase the
percentage of preoligodendrocytes (7 6 2%) (Fig. 6B). These
results indicate that sErbB3 treatment of growing neurospheres
can selectively prime the precursors for oligodendrocyte differ-
entiation. The preferential recruitment of these cells from the
undifferentiated NPs could also indicate an accelerated process of
differentiation in the presence of the Nrg-1 inhibitor.
The effect of the soluble receptor was compared with that of
GGF2 before and after adhesion. GGF2 treatment increased the
number of cells in the outgrowth and moderately decreased the
percentage of preoligodendrocytes (from 5 6 1 to 3 6 0.3%) (Fig.
6A,B). In addition, GGF2 increased the percentage of GFAP-
positive cells from 0.5 6 0.2 to 4 6 0.5% as described previously
(Pinkas-Kramarski et al., 1994), whereas the percentage of neu-
ronal progenitors was not significantly changed (Fig. 6B). These
results indicate that recombinant Nrg-1 to some degree favors
development of astrocytes over that of oligodendrocytes from the
NP pool.
Because soluble ErbB receptor emerged as a strong inducer of
oligodendrocyte development, we also studied the effect of sErbB3
pretreatment of growing neurospheres on expression of GC and
MBP, two markers of postmitotic oligodendrocytes. Such sErbB3
pretreatment resulted in a significant increase in the percentage of
GC-positive cells after adhesion (from 6 6 2% in control to 12 6
Figure 5. Effect of soluble ErbB3 on neurosphere formation
and growth. A, Purification of soluble ErbB3 (sErbB3) and b
subunit of glycine receptor (sGlyr). Western blot analysis of
total extract of sErbB3- and sGlyr-transfected CHO cells
(lane 1) or of purified protein (lane 2). Detection with an
anti-myc antibody that recognized Myc tag present on
sErbB3 and sGlyr constructs revealed a single band of ;80
and 75 kDa, respectively, for sErbB3 and sGlyr. B, Phase-
contrast micrographs show the reduction in size of neuro-
spheres cultured for 6 d in the presence of 0.5 mg/ml of
sErbB3 compared with untreated control cultures or neuro-
spheres grown in the presence of 0.5 mg/ml of sGlyr. Scale
bar, 100 mm. C, D, The neurospheres were grown for 6 d in
the presence of different concentrations of sErbB3 or of 1
mg/ml of sGlyr. The diameter of 50 spheres (C) and the total
number of spheres (D) for each condition were determined.
Treatment with sErbB3 decreased the size (C) and number
(D) of neurospheres in a dose-dependent manner. Each bar
represents the mean 6 SEM of triplicate experiments done
three times. E, F, The neurospheres were grown for 2 d in the
presence or absence of 0.5 mg/ml of sErbB3 or of sGlyr.
BrdU was added to the culture 24 hr before staining ( E).
Spheres were plated onto poly-D-lysine/fibronectin-coated
coverslips for 30 min at 37°C, then fixed and processed for
BrdU (E) or TUNEL (F) staining and counterstained with
DAPI to visualize all nuclei within the spheres. The ratio of
BrdU-positive cells (E) and TUNEL-positive cells (F) to
total cells was determined within at least 30 spheres. Each bar
represents the mean 6 SEM of three experiments with trip-
licates. Treatment with sErbB3 decreased the proliferative
rate of neurospheres, but more so at 2 d than 6 d (E), and
increased cell apoptosis at both time points (F). Student t
test: ***p , 0.01.
Table 2. sErbB3 biological activity on rat Schwann cells









0 2130 6 310 0 35877 6 1257
100 2370 6 245 40 33718 6 1932
500 2733 6 336 85 31465 6 1561
1000 2778 6 890 170 20042 6 2119
2000 2376 6 258 250 16050 6 870
Schwann cell cultures were exposed to various concentrations of sErbB3 alone
(Effect on mitosis) or in the presence of GGF2 at 20 ng/ml (Inhibition of GGF2-
induced mitosis). The tritiated thymidine incorporation was performed between 24
and 48 hr and is expressed in dpm per mg of protein per sample 6 SEM of triplicate
cultures.
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2%) and a doubling of the percentage of MBP-positive cells (from
1 6 0.3% in control to 2 6 0.4%) (Fig. 6C). Interestingly, when
sErbB3 treatment was maintained throughout neurosphere growth
and differentiation, the percentage of GC-positive cells (Fig. 6C)
further increased from 12 6 2 to 16 6 3%, and the complexity of
oligodendrocyte processes was increased when compared with con-
trol (Fig. 6D). As observed with the O4 labeling, addition of
sErbB3 exclusively after adhesion did not significantly modify the
percentage of GC- and MBP-positive cells versus controls (Fig.
6C). Together these results demonstrate that sErbB3 favored oli-
godendrocyte development and may accelerate their differentiation.
DISCUSSION
Our study demonstrates that NPs within the embryonic striatum
and grown in neurospheres synthesize multiple NRG-1 tran-
scripts and proteins as well as the ErbB2 and ErbB4 receptors.
Although both secreted and transmembrane type III NRG-1
isoforms were identified by RT-PCR in growing neurospheres,
only one dominant Nrg-1, the transmembrane SMDF/CRD–
NRG isoform, was demonstrated by Western analysis. ErbB
receptors and Nrg-1 are coexpressed in NPs, and treatment with
sErbB3 (which binds Nrg-1 ligands) decreases proliferation and
increases apoptosis of these precursors, resulting in a significant
reduction in neurosphere size and number. Thus Nrg-1 made by
striatal neural precursors promotes their growth via autocrine or
paracrine signaling, or both. Furthermore, the ability of GGF2 to
enhance only the initial stage of neurosphere growth in low-
density cultures suggests that the level of Nrg-1 bioactivity was
rapidly saturating in this culture system. After adhesion, GGF2
treatment favored astrocyte rather than oligodendrocyte differ-
entiation (Pinkas-Kramarski et al., 1994; Canoll et al., 1996,
1999). In contrast, sErbB3 pretreatment of growing neurospheres
acts as an inducer or accelerator of oligodendrocyte generation
with no apparent effects on neuronal and astrocyte lineages.
These effects were specific because an unrelated soluble receptor
Figure 6. Effect of soluble ErbB3 and
GGF2 on neurosphere differentiation. The
neurospheres were grown for 6 d in the
presence of 0.5 mg/ml of sErbB3 or sGlyr or
in the presence of 100 ng/ml of GGF2 and
then adhered for 2 d to allow differentiation
in the presence or absence of these soluble
proteins. Cultures were either triple labeled
with O4 (for preoligodendrocytes), TujI
(for neuronal cells), or GFAP (for astro-
cytes) antibodies ( B) or double labeled
with O1 and MBP antibodies (for oligoden-
drocytes; C, D) and counterstained with
DAPI (A–D). The ratio of each cell type to
the total number of cells in the outgrowth
was determined. A, The total number of
DAPI-positive cells that migrated out of
each adherent sphere decreased when the
growing spheres were first cultured in the
presence of sErbB3. After adhesion,
sErbB3 shows no effect on the number of
migrating cells. In contrast, addition of
GGF2 increased the total number of cells.
B, The ratio of O4-positive cells increased
by approximately three times in the pres-
ence of sErbB3, whereas the ratio of neu-
ronal cells and astrocytes stayed the same.
The increase in the oligodendrocyte ratio
was not seen if sErbB3 was added only after
neurosphere adhesion (B, C). In the pres-
ence of GGF2, the percentage of oligoden-
drocytes decreased and astrocytes signifi-
cantly increased, whereas the percentage of
neuronal TuJI-positive cells was not signif-
icantly changed. C, The percentage of ei-
ther O1- or MBP-positive cells in the out-
growth had also increased at 2 d after
adhesion of neurospheres pretreated with
sErbB3. This effect was not observed with
neurospheres treated with sErbB3 only af-
ter adhesion. Each bar represents the
mean 6 SEM of three spheres from tripli-
cate experiments done three times. Student
t test: *p , 0.05; **p , 0.02; ***p , 0.01. D,
After sErbB3 treatment, cells coexpressing
MBP ( green dots at arrowheads) in pro-
cesses of galactocerebroside-positive oligo-
dendrocytes (O1 antibody in red) showed
an increased complexity of the processes
(arrow) compared with oligodendrocytes in
control and sGlyr-treated cultures. Scale
bar, 10 mm.
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had no influence on neurosphere growth and differentiation.
These observations lead us to suggest that SMDF/CRD–NRG
signaling and soluble ErbB receptors may both contribute to
oligodendrocyte development from neural stem cells.
Previous studies have shown that FGF2 and EGF enhance
neural stem cell growth in vivo and in vitro (for review, see Bru¨stle
and Dubois-Dalcq, 2001). Nrg-1 can now be added to the factors
promoting the mitosis and survival of NPs isolated from germi-
native zones such as the embryonic striatum. EGF responsiveness
of such striatal precursors is promoted in vitro by a 2 d FGF2
treatment, indicating that FGF2 may induce the EGF receptor,
ErbB1, in these cells (Ciccolini and Svendsen, 1998). In keeping
with this, rat neurospheres express ErbB1 transcripts (B. Rogis-
ter, unpublished observations). Here we described that two Nrg-1
receptors, ErbB2 and ErbB4, were already expressed in the E14
striatum from which NPs were derived. This is in keeping with
the observation that ErbB4 is expressed in the rat E12 and adult
ventricular and subventricular zones (Eagleson et al., 1998;
Steiner et al., 1999). Addition of EGF was required to initiate NP
growth in neurospheres, whereas endogenous Nrg-1 supported
mitosis and expansion of sphere size in the first days in vitro.
ErbB2, which does not bind Nrg-1, is the preferred dimerization
partner for all other ErbB receptors, and these dimers show
increased ligand affinities and prolonged signaling activation
(Olayioye et al., 2000). It is therefore possible that ErbB2 ex-
pressed in our neurospheres formed heterodimers not only with
ErbB4 but also with ErbB1, the EGF receptor. The absence of
ErbB3 transcripts and protein in mouse E14 striatum and neuro-
spheres correlates well with the absence of any in situ hybridiza-
tion signals reported in these regions at this age (Meyer et al.,
1997). ErbB3 is transiently detected in rat E12 cortical progeni-
tors in vitro and at E16 in the germinative zone around the third
ventricle (Eagleson et al., 1998; Kornblum et al., 2000). Thus our
observations on neurospheres suggest an important physiological
role of autocrine or paracrine signaling involving Nrg-1 and
ErbB2–ErbB4 or ErbB4–ErbB4 dimers in NP development in the
forebrain.
Our study also provides evidence that type III transmembrane
SMDF/CRD is the Nrg-1 isoform specifically involved in promot-
ing NP growth in neurospheres. Although the RT-PCR signal
detected the secreted and long transmembrane isoform, Western
blot analysis revealed only the transmembrane type III SMDF/
CRD in the striatum and in differentiated neurospheres. This
does not exclude the possibility that the soluble protein was made
but not detected in our experimental conditions. Although type I
or II NRG-1 transcripts were detected in E14 striatum (Meyer et
al., 1997) (our RT-PCR data), no type II signal and no GGF2
isoform were detected in neurospheres by Western blot or ELISA
on the medium (data not shown). Type III SMDF/CRD isoforms
may be less essential during migration and differentiation of NPs
because the intensity of RT-PCR, fluorescence, and Western blot
signals significantly decreased after neurosphere adhesion. It is
possible that another Nrg-1 isoform influences cell differentiation
at that time. SMDF/CRD Nrg-1 regulates synapse maintenance
and function at the neuromuscular junction as well as Schwann
cell development (Meyer et al., 1997; Wolpowitz et al., 2000).
Indeed, mice deficient in this type III Nrg-1 isoform showed poor
Schwann cell survival, whereas type I and II NRG-1 knock-out
mice, in which the Ig domain was disrupted but the SMDF/CRD
domain was preserved, had normal Schwann cell precursors
(Meyer et al., 1997; Wolpowitz et al., 2000). Our results now
suggest that this pleiotrophic type III Nrg-1 isoform can also
promote NP growth.
The strong and specific effect of sErbB3 treatment on oligo-
dendrocyte generation from NPs is of particular interest. When
this Nrg-1 inhibitor was added during sphere growth for 6 d, the
relative oligodendrocyte population in the outgrowth had tripled
compared with control, whereas the proportion of neuronal and
astrocytic cells in the outgrowth remained unchanged. There are
several possible interpretations of these findings (Fig. 7). The
Figure 7. Diagram of the hypothetical mechanisms of action
of Nrg-1 signaling in NPs and oligodendrocyte differentia-
tion. NPs, growing in neurospheres, strongly expressed
Nrg-1. After adhesion, NPs migrated out of neurospheres
and progressively differentiated into astrocytes, neurons, and
oligodendrocytes, all weakly expressing Nrg-1. Addition of
sErB (in this study, sErbB3) during neurosphere formation
increased NP apoptosis, decreased NP proliferation rate, and
increased oligodendrocyte differentiation, suggesting an in-
crease in OP selection or commitment, or both. The f ramed
panels show two different interpretations of these data. In a,
sErbB blocks endogenous Nrg-1, soluble or transmembrane,
decreasing its mitotic and survival effect on NPs; in b, sErbB
binds to transmembrane Nrg-1 to trigger an intracellular
signal of an unknown nature.
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simplest one is that Nrg-1 acts not only as mitogen for NPs but
also inhibits differentiation of early OPs (Canoll et al., 1996,
1999). When Nrg-1 is downregulated at the time of differentiation
or inhibited by sErbB3, OPs would exit the cell cycle and differ-
entiate rapidly into oligodendrocytes. Another possibility is that
the overall reduction of NP numbers attributable to sErb3 treat-
ment could result in a preferential decrease in neuronal progen-
itors or astrocytes, or both. Because Nrg-1 promotes embryonic
retinal neuron survival and differentiation (Bermingham-
McDonogh et al., 1996) and prevents apoptosis and accelerates
the maturation of astrocytes (Pinkas-Kramarski et al., 1994),
sErb3 could cause a decrease in these two populations. However
Nrg-1 is also a potent survival factor for differentiated oligoden-
drocytes (Fernandez et al. 2000; Flores et al. 2000), and therefore
sErbB should equally decrease their number, but the reverse is
observed here. Because sErbB3 acts at an early stage during
neurosphere growth, it may positively select for precursors pre-
committed to an oligodendrocyte fate. These precursors would
then go on to differentiate into oligodendrocytes after adhesion,
a process that may be favored by the decrease in Nrg-1 at that
time. Finally, PDGF, which is made in neurospheres (Rogister,
unpublished observations) and is playing an important role in
oligodendrocyte development (Calver et al., 1998), may compen-
sate for the decrease in functional Nrg-1 and preferentially stim-
ulate OP to divide within the sphere, resulting in increased
generation of oligodendrocytes. The mechanisms considered here
are in keeping with the importance of short-range membrane-
bound regulatory signals in stem cell differentiation (Tsai and
McKay, 2000).
What then is the physiological stimulus of differentiation of
oligodendrocytes in vivo? Interestingly, two isoforms of the
ErbB4 receptor have been described that differ in the juxtamem-
brane portion of the extracellular domain JMa [(23 amino acid
(aa)], which is cleavable, and JMb (13 aa), which is noncleavable
(Elenius et al., 1997; Rio et al., 2000). These two forms of ErbB4
receptors are expressed in a tissue-specific manner and have been
detected in cerebellum (Elenius et al., 1997). Proteolytic cleavage
in the JMa region is induced by TACE (TNF-a converting
enzyme), a member of the metalloprotease desintegrin family
(ADAM) (Rio et al., 2000), the differential expression of which in
the germinative zone and neural precursors is presently un-
known. Moreover, an EGF domain peptide of a b1 Nrg-1 isoform
can induce this ErbB4 cleavage (Zhou and Carpenter, 2001). The
ability of ErbB4 to be cleaved leads us to propose that, in vivo,
soluble ErbB4 could stop mitosis of oligodendrocyte progenitors
triggered by Nrg-1, allowing their differentiation, as does sErbB3
in our in vitro model. Soluble ErbB4 could act on oligodendrocyte
determination before the downregulation of Nrg-1 expression by
differentiated cells. Thus one should determine whether soluble
ErbB4 is released in a developmentally regulated manner by
neural precursors and their derivatives and whether this would
result in oligodendrocyte differentiation. Moreover, if mature
neurons and their processes express this receptor as our data
suggest (Fig. 4D), these cells could release ErbB4 in a regulated
way to promote oligodendrocyte differentiation along axons.
In conclusion, our study demonstrates how Nrg-1 promotes the
growth of NPs and underlines the importance of Nrg-1 signaling
in oligodendrocyte development. This process could occur in two
steps. First, Nrg-1 signaling would enhance and maintain the
growth of NPs and early oligodendrocyte precursors, and subse-
quently the regulated release of a soluble Nrg-1 receptor would
inhibit mitosis and induce (or permit) oligodendrocyte differen-
tiation. Future investigations in vivo and in vitro may help deter-
mine whether this hypothesis is correct.
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